Avelo, VIVOLTA, and BLINK Win €1.5M Eurostars Grant to Develop New Solution for Diagnosing Lower Respiratory Tract Infections
The project will span two years and lay the foundation for market launch in 2027.
- The project will span two years and lay the foundation for market launch in 2027.
- The solution will be the world’s first breath-based system capable of fast, accurate, and specific diagnosis of LRTIs, and will be simple-to-use for maximum adoption around the world.
- Joining forces with VIVOLTA and BLINK will help us to develop and validate our AveloCollect breath sampling kit, which has the potential to revolutionize the field of respiratory medicine.
- After adding the breath sample from the AveloCollect device, the Respirex cartridge can be rapidly analyzed in BLINK’s first-of-its-kind point-of-care analyzer, the BLINK ONE.